Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease

Summary We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD). Since the introduction of tumor necrosis factor-alpha (TNF-α) antagonists, various microbiologic agents have been reported to cause pneumonia following their...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infection Vol. 54; no. 1; pp. e29 - e32
Main Authors Ahmad, Nasir M, Ahmad, Khalid M, Younus, Faheem
Format Journal Article
LanguageEnglish
Published England 01.01.2007
Subjects
Adenovirus
Adenovirus Infections, Human - etiology
Adult
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Crohn Disease - complications
Crohn Disease - drug therapy
Humans
Infectious Disease
Infliximab
Male
Pneumonia, Viral - etiology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
United States
United States
Pneumonia
Infliximab
Adenovirus
Tumor necrosis factor
Online AccessGet full text

Cover

More Information
Summary:Summary We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD). Since the introduction of tumor necrosis factor-alpha (TNF-α) antagonists, various microbiologic agents have been reported to cause pneumonia following their administration. To our knowledge, AVP following therapy with TNF-α antagonists has not been reported in English literature. We present a brief review of the mechanism of action of TNF-α antagonists and their ability to predispose to various infections including viral pneumonia by interfering with the immune response.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2006.03.025